title: Vasopressinergic neurons in rats in ontogenesis: responses to salt loading and their modulation by noradrenergic afferents.
abstract: Salt loading in adult mammals leads to increased vasopressin secretion by vasopressinergic neurons in the supraoptic nucleus, which is mediated by the actions of a number of hormones and neurotransmitters, including noradrenaline. The present study addressed identification of the stage of ontogenesis at which vasopressinergic neurons start to respond to salt loading and when the noradrenalinergic regulation of this process begins. Studies were performed on rats at embryonic day 21 (E21), postnatal day 3 (P3), and postnatal day 13 (P13) using immunocytochemical and in situ hybridization. Animals were subjected to salt loading, in some cases on the background of the alpha1-adrenoceptor inhibitor prazosin. Salt loading in rats of all age groups induced increases in the synthesis of vasopressin mRNA, probably accompanied by increased synthesis of vasopressin peptide. At E21 and P3, intraneuronal vasopressin levels were increased; there was no change at P13. In salt loading on the background of prazosin administration, vasopressin mRNA and vasopressin contents at E21 showed no change, while at P3 they were increased, which is evidence of the inhibitory effect of noradrenaline on vasopressin expression in the early postnatal period. Thus, vasopressinergic neurons start to respond to salt loading at the end of the prenatal period with increases in vasopressin expression; noradrenergic afferents have inhibitory influences on vasopressin expression in the early postnatal period.
authors.affiliation: Hormonal Regulation Laboratory, N. K. Kol'tsov Institute of Developmental Biology, Russian Academy of Sciences, 26 Vavilov Street, Moscow, Russia.
authors.forename: M A
authors.initials: MA
authors.lastname: Abramova
authors.forename: M V
authors.initials: MV
authors.lastname: Ugryumov
authors.forename: A
authors.initials: A
authors.lastname: Kalas
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001069:Appetite Regulation / Q000187:drug effects / Q000502:physiology*; D005260:Female; D018507:Gene Expression Regulation, Developmental / Q000187:drug effects / Q000502:physiology; D007150:Immunohistochemistry; D008297:Male; D009475:Neurons, Afferent / Q000187:drug effects / Q000378:metabolism*; D011224:Prazosin / Q000494:pharmacology; D011247:Pregnancy; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017673:Sodium Chloride, Dietary / Q000494:pharmacology; D018709:Statistics, Nonparametric; D013495:Supraoptic Nucleus / Q000187:drug effects / Q000196:embryology / Q000378:metabolism*; D014667:Vasopressins / Q000235:genetics / Q000378:metabolism*; D014882:Water-Electrolyte Balance / Q000502:physiology
chemical_list: D000317:Adrenergic alpha-Antagonists; D012333:RNA, Messenger; D017673:Sodium Chloride, Dietary; D014667:Vasopressins; D011224:Prazosin